APPENDIX 1.

AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES—2013 ACCF/AHA KEY DATA ELEMENTS AND DEFINITIONS FOR MEASURING THE CLINICAL MANAGEMENT AND OUTCOMES OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND CORONARY ARTERY DISEASE

Committee Member	Employer/Title	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Christopher P. Cannon, Chair	Brigham and Women’s Hospital—Principal Investigator, TIMI Study Group	Alnylam Automedics Medical Systems Bristol-Myers Squibb CSL Behring Pfizer	None	Automedics Medical Systems	Accumetrics AstraZeneca Aventis-Bristol-Myers Squibb Essentialis GlaxoSmithKline Merck Merck-Schering Plough Regeneron/Sanofi Schering Plough Takeda	None	None
Ralph G. Brindis	Oakland Kaiser Medical Center—Senior Regional Advisor for Cardiovascular Diseases	None	None	None	None	None	None
Bernard R. Chaitman	St. Louis University School of Medicine–Core ECG Laboratory—Director, Cardiovascular Research	AstraZeneca CV Therapeutics Eli Lilly Merck Pfizer Sanofi-aventis	AstraZeneca CV Therapeutics Pfizer	None	CV Therapeutics Merck	None	None
David J. Cohen	St. Luke’s Medical Center—Director, Cardiovascular Research	Boehringer Ingelheim Eli Lilly Medtronic	Daiichi Sankyo Eli Lilly	None	AstraZeneca Boston Scientific Daiichi Sankyo Edwards Lifesciences Eli Lilly Medtronic St. Jude Medical	None	None
J. Thomas Cross, Jr	MedStudy Corporation—Director of Medical Education	None	None	None	None	None	None
Joseph P. Drozda, Jr	Mercy Health—Director of Outcomes Research	None	None	None	None	None	None
Francis M. Fesmire	University of Tennessee Health Science Center—Associate Professor	None	None	None	None	None	None
Dan J. Fintel	Northwestern University Feinberg School of Medicine—Professor of Medicine	Merck-Schering Plough Sanofi-aventis Schering Plough	AstraZeneca Merck-Schering Plough Sanofi-aventis Schering Plough	None	None	Merck-Schering Plough Sanofi-aventis Schering Plough	None
Gregg C. Fonarow	Ahmanson-UCLA Cardiomyopathy Center Division of Cardiology	None	AstraZeneca Aventis Bristol-Myers Squibb Bristol-Myers Squibb Sanofi GlaxoSmithKline Guidant Medtronic Merck-Schering Plough Nitromed Pfizer St. Jude	None	GlaxoSmithKline Medtronic	None	None
Keith A. Fox	Edinburgh University Chancellor’s Building—President, British Cardiac Society	None	None	None	None	None	None
Darryl T. Gray	Agency for Healthcare Research Quality—Medical Officer	None	None	None	None	None	None
Robert A. Harrington	Duke Clinical Research Institute, Duke University Medical Center—Professor of Medicine, Director	None	None	None	None	None	None
Karen A. Hicks	U.S. Food and Drug Administration—Medical Officer	None	None	None	None	None	None
Judd E. Hollander	University of Pennsylvania Department of Emergency Medicine	None	None	None	Abbott Allere Brahms Nanosphere Siemens	None	None
Harlan Krumholz	Yale University School of Medicine—Professor of Medicine	Alere Amgen United Health VHA, Inc	None	None	American College of Cardiology Colorado Foundation for Medical Care	None	None
Darwin R. Labarthe	Centers for Disease Control and Prevention—retired	None	None	None	None	None	None
Janet B. Long	Rhode Island Cardiology Center—Nurse Practitoner	None	AstraZeneca	None	None	None	None
Alice M. Mascette	National Heart, Lung, and Blood Institute Division of Cardiovascular Sciences—Senior Clinical Science Advisor	None	None	None	None	None	None
Connie Meyer	Johnson County Med-Act (Olathe, KS)—Emergency Medical Services Captain	None	None	None	None	None	None
Eric D. Peterson	Duke Clinical Research Institute, Duke University Medical Center—Professor of Medicine; Director, Cardiovascular Outcomes	None	Genentech	None	Aventis-Bristol-Myers Squibb Corgentech CV Therapeutics Merck Schering Plough	None	None
Martha J. Radford	New York University Hospitals Center—Professor of Medicine, Chief Quality Officer	None	None	None	None	None	None
Matthew T. Roe	Duke Clinical Research Institute, Duke University Medical Center—Associate Professor of Medicine	Genentech Novartis	Aventis-Bristol-Myers Squibb Daiichi Sankyo KAI Pharmaceuticals Schering Plough	None	Aventis-Bristol-Myers Squibb Daiichi Sankyo Eli Lilly KAI Pharmaceuticals Schering Plough	None	None
James B. Richmann	Bluejay Consulting—Consultant	None	None	None	None	None	None
Harry P. Selker	Tufts Medical Center—Executive Director of the Institute for Clinical Research and Health Policy Studies; Tufts University—Dean of Tufts Clinical and Translational Science Institute	None	None	None	None	None	None
David M. Shahian	Massachusetts General Hospital—Associate Director of the Codman Center for Clinical Effectiveness in Surgery	None	None	None	None	None	None
Richard E. Shaw	California Pacific Medical Center—Director–Research, Quality and Education	None	None	None	Duke Clinical Research Institute Schering Plough	None	None
Sharon Sprenger	The Joint Commission	None	None	None	None	None	None
Robert Swor	William Beaumont Hospital	None	None	None	None	None	None
James A. Underberg	NYU Langone Center for Cardiovascular Disease Prevention; Bellevue Hospital Lipid Clinic—Director	Genzyme Liposcience	Aboott AstraZeneca Daiichi Sankyo DiaDexus Eli Lilly GlaxoSmithKline Kowa	None	• Kowa	None	None
Frans Van de Werf	University Hospitals Leuven—Professor of Cardiology	None	None	None	None	None	None
Bonnie H. Weiner	St. Vincent Hospital Worcester Medical Center—Director of Interventional Cardiology Research	None	None	None	None	None	None
William S. Weintraub	Christiana Care Health System—Section Chief, Cardiology	AstraZeneca Bayer Bristol-Myers Squibb Cardionet Eli Lilly Pfizer Shionogi	None	None	Abbott AstraZeneca Bristol-Myers Squibb Otsuka Sanofi-aventis	None	2011—Oral contraceptive litigation—represented defendant for general epidemiologic testimony 2009—Aprotinin litigation—represented defendant as an expert witness for Aprotinin

This table represents the relationships of committee members with industry and other entities that were reported by authors to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of $10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.